Phase 2, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and antiviral activity of JNJ-63623872 in combination with oseltamivir in adult and elderly adolescent patients hospitalized for influenza A infection.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: JANSSEN-CILAG INTERNATIONAL NV
- Phase: II
- Execution start: 02/11/2015
- End of execution: 30/04/2017
- IP: JOSE HERNANDEZ QUERO